Removing Time from the Equation
X-Therma enables the robust preservation of cells, tissues, organs, and other biologics by leveraging our proprietary peptoid. The peptoid inhibits lethal ice crystals, allowing long-term sub-zero storage of biological materials while maintaining unparalleled functionality and viability.
How it Began
When she was 8 years old, Xiaoxi’s beloved grandfather passed away. If he had received a donor liver, he would have had more time to spend with loved ones.
Xiaoxi has since dedicated her life to finding a solution that increases organ availability. In 2014 she obtained her doctorate in medicinal chemistry from SUNY-Buffalo. Soon after, she established X-Therma to bring her vision of eradicating organ waitlists to life.
X-Therma History
2015
Xiaoxi Wei, CEO began her research work for X-Therma at Lawrence Berkeley National Laboratory. She received her first grant awarded to X-Therma. Provisional patent filed.
2016
Only one year later X-Therma had two additional grants in implementation and a team of four. First successful proof of concept for novel preservation of cell lines.
2017
X-Therma now has five grants running simultaneously and filed additional provisional patents.
2018
X-Therma partnered with Johns Hopkins University and Dr. Gerald Brandacher on several grants. X-Therma awarded first patent claim set!
2019
Successful in vivo mouse heart transplant with Johns Hopkins University.
2020
X-Therma survived the Covid-19 pandemic and was able to continue with successful ex vivo organ transplantations.
2021
X-Therma closed an oversubscribed $13M Series A financing led by LOREA AG. The European office was opened.
2022
The FDA designated X-Therma's proprietary organ preservation solution, XT-ViVo®, and TimeSeal® Organ Transport Device, Breakthrough Device status.
News
Science Chops Alone Don’t Cut It: The Entrepreneurial Growth Struggle
By Mark Kline, Founder and CTO, X-Therma In the eight years since launching X-Therma, we’ve achieved chemistry breakthroughs that we believe will truly propel the
X-Therma FCOI Policy
X-Therma posts our FCOI to meet requirements of our incoming NIH funding. You can read the policy here: XT_FCOI
XT-Thrive and X-Therma: Next Generation cryopreservation to help advance Cell and Gene Therapies
The world has been waiting for the next scientific breakthrough in cryopreservation. Dimethyl sulfoxide (DMSO), a by-product of the wood industry, has been in use
